CMS: More than 800,000 clinicians will be exempt from MIPS

CMS had expected more than half of Medicare providers to be exempt from the new Merit-based Incentive Payment System (MIPS) in its first year. That ended up being a low estimate, as CMS said 65 percent have been notified they won’t be participating in MIPS for 2017.

A spokesperson for the agency told HealthExec that a total of 806,879 clinicians will be notified they won’t have to participate. Some 418,489 clinicians will have to participate in one of the “pick your pace” options this year to avoid a negative payment adjustment for 2019.

When asked why the estimate included in the final rule implementing the Medicare Access and CHIP Reauthorization Act (MACRA), the CMS spokesperson said the original projections was based on “best data CMS had to present at that time.” The actual eligibility determinations were based on a different time frame than the final rule, running from September 2015 to August 2016, with a “60-day claims run out rather than a flat calendar year.”

The spokesperson also cautioned that the participation number doesn’t include clinicians in the Advanced Alternative Payment Models track. Factoring those participants in, as well as clinicians participating in MIPS as a group, will mean a higher participation total.

Clinicians may be exempt for several reasons, most commonly because they fall under the low-volume threshold for MIPS. To be MIPS eligible, clinicians have to bill $30,000 or more in Medicare Part B allowed charges a year and provide care to more than 100 Part B-enrolled Medicare beneficiaries a year.

These exemptions are judged at the reporting-entity level, meaning some clinicians who would be exempt individually would have to participate if they’re reporting as a group. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.